1FW2:F:F-WUXI BIOLOGICS-00000083 (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.54

Change

-0.16 (-9.62)%

Market Cap

USD 7.56B

Volume

3.57K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

N/A

USD 553.75B
VX1:F Vertex Pharmaceuticals Incorpo..

+4.60 (+1.04%)

USD 108.48B
RGO:F Regeneron Pharmaceuticals Inc

-3.20 (-0.33%)

USD 100.84B
CSJA:F CSL LTD SPON.ADR 2

+0.50 (+0.57%)

USD 85.54B
CSJ:F CSL Limited

+0.44 (+0.25%)

USD 85.42B
0QF:F Moderna Inc

-5.52 (-4.07%)

USD 51.48B
UNC0:F UCB S.A. UNSP.ADR 1/2

+0.50 (+0.75%)

USD 24.67B
UNC:F UCB SA

+1.30 (+0.96%)

USD 24.41B
22UA:F BioNTech SE

-1.55 (-1.75%)

USD 23.22B
1AE:F Argen-X

+11.80 (+3.36%)

USD 21.84B

ETFs Containing 1FW2:F

EWH iShares MSCI Hong Kong ET.. 1,000.00 % 0.48 %

-0.14 (1.28%)

USD 0.50B
FID First Trust Intl Multi-As.. 1.97 % 0.69 %

-0.11 (1.28%)

USD 0.08B
WDIV SPDR® S&P Global Dividen.. 1.52 % 0.40 %

-0.48 (1.28%)

USD 0.20B
WDIV:AU SPDR S&P Global Dividend 1.51 % 0.00 %

+0.23 (+1.28%)

USD 0.25B
FGD First Trust Dow Jones Glo.. 0.00 % 0.58 %

-0.25 (1.28%)

USD 0.55B
3110:HK Global X Hang Seng High D.. 0.00 % 0.00 %

+0.06 (+1.28%)

USD 2.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.11% 10% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.11% 10% F 4% F
Trailing 12 Months  
Capital Gain -70.75% 16% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.75% 16% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.37% 22% F 9% A-
Dividend Return -17.37% 22% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.95% 51% F 39% F
Risk Adjusted Return -58.00% 13% F 7% C-
Market Capitalization 7.56B 96% N/A 84% B

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.